Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jun 27;14:1173524. doi: 10.3389/fimmu.2023.1173524

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2023 Liu, Xu, Guo, Zhan, Quan, Li, Wang, Zhang, Guo and Cao

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Relationship between CD155 mRNA expression and gastric cancer progression. The expression level of CD155 in non-paired tumors (A) and paired tumors (B) in comparison with normal tissues. (C) The overall survival of CD155 in the TCGA database. (D) ROC curve analysis of CD155 diagnosis. (E) The CD155 mRNA expression Level in STAD patients with different pathologic stages. (F) CD155 expression level in five immune subtypes in STAD: C1 (wound healing), C2 (IFN-gamma dominant), C3 (inflammatory), C4 (lymphocyte depleted), and C6 (TGF-b dominant). (G) CD155 expression in five molecular subtypes of STAD: CIN, Chromosome Instable; EBV, Epstein Barr virus; GS, Genetic Stable; HM-SNV, Hypermutated-SNV; HM-indel, Hypermutated-indel. (H) GO and KEGG functional enrichment analysis of CD155. (I) Gene set enrichment analysis. *P < 0.05; ***P < 0.001.